Amyloidosis trials in Japan

In Japan 13 Also abroad 184

13 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
Kumamoto, Osaka, Tokyo, Toyama
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
Phase 1Taking people
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Where
Shibuya City, Suita-shi, Tokyo
Age
18 years and over
People
180 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00
Phase 3Taking people
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Where
Amagasaki, Bunkyo-ku, Fukuoka, Himeji, Kanagawa, Kashihara, Kitakyushu, Kobe, Kumamoto, Kurume-shi, Kyoto, Matsumoto, Nagasaki, Nagoya, Nankoku-shi, Osaka, Sapporo, Suita, Tokyo, Toyama, Tsu, Uwajima-shi, Yamaguchi Prefecture, Yokohama
Age
18 years and over
People
1,280 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07207811
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Bunkyō City, Fukuoka, Kagawa, Kashihara, Kobe, Kumamoto, Kurume, Matsumoto-shi, Nagoya, Nankoku, Niigata, Okayama, Sapporo, Sendai, Suita, Tokyo
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
No phaseTaking people
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
Where
Bunkyō City, Kumamoto, Kurume, Matsumoto, Sendai, Shinjuku, Suita, Tsukuba, Ube, Yufu
Age
18 years and over
People
2,000 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07358078
Phase 3Taking people
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Where
Bunkyo C, Kumamoto, Matsumoto-shi, Suita
Age
18 years to 85 years
People
125 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00
No phaseTaking people
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Where
Tokyo
People
52,121 worldwide
Run by
AstraZeneca
See details and how to joinNCT06355934
Phase 3Not yet taking people in Japan
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
Bunkyo-ku, Kumamoto, Kurume-shi, Kyoto, Matsumoto-shi, Sapporo, Shinjuku-ku, Suita-shi
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
Phase 3Taking people
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Where
Kumamoto, Nagano
Age
18 years to 75 years
People
587 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00
Phase 1/2Taking people
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Where
Kumamoto, Nagoya, Shibuya-ku
Age
18 years and over
People
76 worldwide
Run by
AbbVie
See details and how to joinNCT06158854 · EU 2023-503429-20-00
Phase 3Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Where
Fukuoka, Hamamatsu, Kumamoto, Kurume, Kurume-shi, Matsumoto, Okayama, Osaka, Sapporo, Shinjuku-ku
Age
18 years and over
People
1,400 worldwide
Run by
Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493
Phase 4Taking people
Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers
Where
Bunkyō City, Kumamoto, Kurume-shi, Kyoto, Mitaka-shi, Nagoya, Nankoku-shi, Okayama, Ōtsu, Sagamihara-shi, Sapporo, Shinjuku-ku, Suita-shi, Tsu, Yufu-shi
Age
18 years to 100 years
People
200
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07306949
No phaseTaking people
International Cardiac Amyloidosis Registry
Where
Sagamihara
Age
18 years and over
People
300 worldwide
Run by
Leiden University Medical Center
See details and how to joinNCT06894290